Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients*Sophie Georgin‐Lavialle, Thomas Cluzeau, Benjamin Terrier et al.|British Journal of Dermatology|2021Cited by 414
Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritusJonathan I. Silverberg, Alan Clucas, Andreas Pinter et al.|Journal of Allergy and Clinical Immunology|2019Cited by 268
European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromesRobert Knobler, Thomas Krieg, G. Bali et al.|Journal of the European Academy of Dermatology and Venereology|2017Cited by 261
Chilblains is a common cutaneous finding during the COVID-19 pandemic: A retrospective nationwide study from FranceAdèle de Masson, Sabrina Fourcade-Roch, Jean‐David Bouaziz et al.|Journal of the American Academy of Dermatology|2020Cited by 189
<i>UBA1</i> Variations in Neutrophilic Dermatosis Skin Lesions of Patients With VEXAS SyndromeÈve Zakine, Jean‐David Bouaziz, Bérénice Schell et al.|JAMA Dermatology|2021Cited by 120